This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?
by Zacks Equity Research
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ocular (OCUL) Announces Positive Data on Wet AMD Candidate
by Zacks Equity Research
Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acuity.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -21.74% and 11.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 11.54% and 0.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ocular Therapeutix (OCUL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 14th
by Zacks Equity Research
ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -25.00% and 0.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 19.8% in 4 Weeks, Here's Why the Trend Might Reverse for Ocular Therapeutix (OCUL)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Ocular Therapeutix (OCUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up
by Zacks Equity Research
The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021. Shares rise.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates (Revised)
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 26.09% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 8.70% and 0.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix's (OCUL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Ocular Therapeutix (OCUL).